Figure 5.

TCL1 Upregulates Pluripotency Markers through AKT Activation

(A) Activation of AKT by KLF4 or TCL1. Western blotting was performed using anti-phosphorylated AKT (p-AKT (S473)), anti-AKT, or anti-α-tubulin antibody for the whole-cell extracts prepared from MEFs, iPSCs(Low-K), iPSCs(High-K), or iPSCs(Low-K) expressing TCL1 at day 30.

(B) The intensity of each band in (A) was quantified using LAS4000. Data represent means ± SEM of three independent experiments. ^∗p < 0.05.

(C and D) Cdh1 and Rex1 mRNA levels in MEFs reprogrammed by SeVdp(fK-OSM) with or without Shield1 for 30 days. The cells were treated only with an inhibitor (1 μM MK2206) or activator (4 μg/mL SC79) of AKT (C), or infected with a TCL1-expressing retrovirus and then treated with MK2206 (D). Data represent means ± SEM of three independent experiments. ^∗p < 0.05, ^∗∗∗p < 0.005.

See also Figures S5, S6, and S7 and Table S1.